South Korea-based Samsung Biologics (207940.KS) has signed a strategic partnership with Kanaph Therapeutics, it was reported on Wednesday.
The contract has been signed to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
According to Kanaph Therapeutics, the product is aimed at autoimmune diseases by inhibiting the alternative pathway of the complement system. According to the contract, Samsung Biologics is to offer a complete scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial